“…MAT1 (Talukder et al, 2003); MICoA (Mishra et al, 2003); NRIF3 (Talukder et al, 2004); and LMO4 (Singh et al, 2005)] and via recruitment of distinct transacting factor complexes to the target genes (Kang et al, 2014). In addition to blocking ER-transactivation, MTA1 also inhibits the transcription of breast cancer type 1 susceptibility gene (Molli et al, 2008), PTEN (Reddy et al, 2012), p21 WAF1 (Li and Kumar, 2010), guanine nucleotide-binding protein G(i) subunit alpha-2 (Ohshiro et al, 2010), SMAD family member 7 (SMAD7) (Salot and Gude, 2013), nuclear receptor subfamily 4 group A member 1 (Yu et al, 2013), and homeobox protein SIX3 (Manavathi et al, 2007), and represses BCL11B during T-cell leukemia (Cismasiu et al, 2005). …”